Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.59 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.59 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.59 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.59 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.59 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | EDNRB | P24530 | 1/20 | 0.41 |
| ▸ | EDNRA | P25101 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | GPR3 | P46089 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HBB | P68871 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27558512 | 0.82 | HDAC3 (0.61) | HDAC3HDAC4HDAC7HDAC8HDAC6 | |
| Benzene SCHEMBL28538497 | 0.80 | HDAC3 (0.59) | HDAC3HDAC4HDAC7HDAC8HDAC6 | |
| SCHEMBL30001332 | 0.80 | HDAC3 (0.59) | HDAC3HDAC4HDAC7HDAC8HDAC6 | |
| SCHEMBL40500 | 0.80 | HDAC3 (0.59) | HDAC3HDAC4HDAC7HDAC8HDAC6 | |
| SCHEMBL7043488 | 0.78 | HDAC3 (0.57) | HDAC3HDAC4HDAC7HDAC8HDAC6 | |
| SCHEMBL15125189 | 0.78 | HDAC3 (0.57) | HDAC3HDAC4HDAC7HDAC8HDAC6 | |
| SCHEMBL4796539 | 0.78 | HDAC3 (0.57) | HDAC3HDAC4HDAC7HDAC8HDAC6 | |
| SCHEMBL9010860 | 0.78 | HDAC3 (0.57) | HDAC3HDAC4HDAC7HDAC8HDAC6 | |
| SCHEMBL3143561 | 0.78 | ATM (0.61) | HDAC3HDAC4HDAC7HDAC8HDAC6 | |
| SCHEMBL30250175 | 0.78 | ATM (0.61) | HDAC3HDAC4HDAC7HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0620216-B1 | Benzamide derivatives and their use as vasopressin antagonists | FUJISAWA PHARMACEUTICAL CO (JP) | 2003-01-08 | — | — | EP | claimed |
| EP-3466934-B1 | SULFONAMIDE COMPOUNDS OR SALT THEREOF AS RIBONUCLEOTIDE REDUCTASE INHIBITORS FOR TREATING CANCER | TAIHO PHARMACEUTICAL CO LTD (JP) | 2024-03-27 | — | — | EP | disclosed |
| EP-3871673-B1 | NOVEL INDAZOLE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2024-01-03 | — | — | EP | disclosed |
| US-11696917-B2 | Agent enhancing antitumor effect using pyrazolo[3,4-d]pyrimidine compound | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-07-11 | — | — | US | disclosed |
| CN-110740991-B | Novel biphenyl compound or salt thereof | 大鹏药品工业株式会社 | 2023-07-04 | — | — | CN | disclosed |
| US-20230181536-A1 | ANTICANCER COMBINATION THERAPY WITH N-(1-ACRYLOYL-AZETIDIN-3-YL)-2-((1H-INDAZOL-3-YL)AMINO)METHYL)-1H-IMIDAZOLE-5-CARBOXAMIDE INHIBITOR OF KRAS-G12C | TAIHO PHARMACEUTICAL CO LTD (JP) | 2023-06-15 | — | — | US | disclosed |
| EP-3632443-B1 | ANTI-TUMOR EFFECT POTENTIATOR USING A BIPHENYL COMPOUND | TAIHO PHARMACEUTICAL CO LTD (JP) | 2023-06-07 | — | — | EP | disclosed |
| US-20230064254-A1 | THERAPEUTIC AGENT CONTAINING FUSED PYRIMIDINE COMPOUND AS ACTIVE INGREDIENT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-03-02 | — | — | US | disclosed |
| US-20230049402-A1 | NOVEL PHENOL COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO. LTD. (JP) | 2023-02-16 | — | — | US | disclosed |
| US-20230023023-A1 | 4-AMINOBUT-2-ENAMIDE DERIVATIVES AND SALTS THEREOF | ASTEX THERAPEUTICS LIMITED (GB) | 2023-01-26 | — | — | US | disclosed |
| WO-1996030395-A2 | CYSTEINE PROTEASE INHIBITOR | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-10-03 | — | — | WO | disclosed |
| WO-1996017850-A1 | CEPHEM COMPOUNDS AND PHARMACEUTICAL USE THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-06-13 | — | — | WO | disclosed |
| US-5521170-A | VASOPRESSIN ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-05-28 | — | — | US | disclosed |
| US-5387710-A | Ethanolamine derivatives having sympathomimetic and anti-pollakiuria activities | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-02-07 | — | — | US | disclosed |
| WO-1994025427-A1 | ETHANOLAMINE DERIVATIVES USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-11-10 | — | — | WO | disclosed |
| EP-0620216-A1 | Benzamide derivatives and their use as vasopressin antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-10-19 | — | — | EP | disclosed |
| EP-0583485-A1 | ETHANOLAMINE DERIVATIVES HAVING SYMPATHOMIMETIC AND ANTI-POLLAKIURIA ACTIVITIES. | FUJISAWA PHARMACEUTICAL CO (JP) | 1994-02-23 | — | — | EP | disclosed |
| EP-0579833-A1 | ETHANOLAMINE DERIVATIVES WITH ANTI-POLLAKIURIA ACTIVITY. | FUJISAWA PHARMACEUTICAL CO (JP) | 1994-01-26 | — | — | EP | disclosed |
| WO-1993015041-A1 | ETHANOLAMINE DERIVATIVES HAVING SYMPATHOMIMETIC AND ANTI-POLLAKIURIA ACTIVITIES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-08-05 | — | — | WO | disclosed |
| WO-1992018461-A1 | ETHANOLAMINE DERIVATIVES WITH ANTI-POLLAKIURIA ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230023023-A1 | 4-AMINOBUT-2-ENAMIDE DERIVATIVES AND SALTS THEREOF | KRAS, NRAS, HRAS | HDAC3 926/4885HDAC4 1522/4885HDAC7 2595/4885 |
| US-11696917-B2 | Agent enhancing antitumor effect using pyrazolo[3,4-d]pyrimidine compound | ZYX, DPYD, ZFX | HDAC3 601/4885HDAC4 276/4885HDAC7 1345/4885 |
| US-20230064254-A1 | THERAPEUTIC AGENT CONTAINING FUSED PYRIMIDINE COMPOUND AS ACTIVE INGREDIENT | GNAQ, REN, GLS | HDAC3 3223/4885HDAC4 3438/4885HDAC7 675/4885 |
| US-20230181536-A1 | ANTICANCER COMBINATION THERAPY WITH N-(1-ACRYLOYL-AZETIDIN-3-YL)-2-((1H-INDAZOL-3-YL)AMINO)METHYL)-1H-IMIDAZOLE-5-CARBOXAMIDE INHIBITOR OF KRAS-G12C | KRAS, NRAS, HRAS | HDAC3 1353/4885HDAC4 2364/4885HDAC7 2010/4885 |
| US-20230049402-A1 | NOVEL PHENOL COMPOUND OR SALT THEREOF | MYB, MLX, EP300 | HDAC3 255/4885HDAC4 617/4885HDAC7 748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.